Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen Inc. (NASDAQ:AMGN ) Oppenheimer 33rd Annual Healthcare Conference March 13, 2023 2:00 PM ET Company Participants Arvind Sood - Vice President, Investor Relations Susan Sweeney - Senior Vice President, Global Marketing, Access and Capabilities Conference Call Participants Jay Olson - Oppenheimer & Co. Inc. Jay Olson Hello, everyone. And welcome to Oppenheimer's 33rd Annual Healthcare Conference.

Amgen Inc. (AMGN) Oppenheimer 33rd Annual Healthcare Conference (Transcript)

AbbVie

Ares Capital

BlackRock Taxable Municipal Bond Trust

BlackRock Science & Technology

Clorox

Digital Realty Trust

iShares MSCI EAFE Growth ETF

iShares MSCI EAFE Value ETF

Fastenal

Flaherty & Crumrine Preferred Securities Income Fund Inc

Home Depot

Johnson & Johnson

Kimberly-Clark

Lockheed Martin

McDonald's

Magellan Midstream Partners

Altria

NextEra Energy

PIMCO Dynamic Income Fund

Cohen & Steers Quality Income Realty Fund

iShares 1-3 Year Treasury Bond ETF

Proshares Short 20+ Year Treasury

abrdn World Healthcare Fund 

iShares 20+ Year Treasury Bond ETF

The stock market is inherently volatile. With the economy going through the boom and bust cycles more frequently, the extreme ups and downs of the market are inevitable. For most conservative investors, especially retirees, it's very difficult to tolerate large and deep drawdowns. However, it is almost impossible to avoid these issues with index investing.

The Near-Perfect Portfolio: Sleep Well During Turbulent Times

THOUSAND OAKS, Calif., March 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 Oppenheimer Healthcare Conference at 2:00 p.m.

AMGEN TO PRESENT AT THE 33rd ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE

Amgen Inc. (NASDAQ:AMGN ) 43rd Annual TD Cowen Healthcare Conference March 8, 2023 11:10 AM ET Company Participants Peter Griffith - Executive Vice President and Chief Financial Officer Murdo Gordon - Executive Vice President of Global Commercial Operations Conference Call Participants Yaron Werber - TD Cowen Yaron Werber [Call starts abruptly] Once again to the 43rd Annual Healthcare Conference. And it's actually the first TD Cowen Healthcare Conference.

Amgen Inc. (AMGN) Presents at 43rd Annual TD Cowen Healthcare Conference (Transcript)

Boeing

Cisco Systems

Chevron

Disney

Dow Inc

Coca-Cola

UnitedHealth Group

Verizon

Walgreens

Walmart

"The Dow [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration." – Dow Jones & Co. The highest-yield 10 are March's Dogs of the Dow: JNJ, KO, CSCO, AMGN, CVX, DOW, IBM, WBA, MMM, and VZ, averaging a 4.41% annual yield.

2 March Dogs Of The Dow To Buy, 4 More To Watch

Alphabet

Southern Company

Amgen's growing business should get a boost from a couple of recent acquisitions. Even amid elevated inflation, Alphabet's business generates significant profits and tons of free cash flow.

A Bull Market Is Coming: 3 Stocks Near Their 52-Week Lows to Buy Now

THOUSAND OAKS, Calif. , March 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the second quarter of 2023.

AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND

American Electric Power Company

Broadcom

Comcast

ConocoPhillips

Medtronic

Morgan Stanley

Pfizer

PNC Financial Services

Phillips 66

Sempra Energy

Truist Financial

U.S. Bancorp

Vanguard High Dividend Yield ETF

There are 17 stocks on my high-yield watchlist for March 2023. The majority of the stocks on my watchlist are undervalued based on dividend yield theory.

High Yield Stock Watchlist: March 2023

Arbor Realty Trust

Analog Devices

Automatic Data Processing

Assured Guaranty

AMERISAFE

Auburn National Bancorporation

Avient Corp

Atlantica Sustainable Infrastructure

Best Buy

Becton, Dickinson and Co.

Badger Meter

BWX Technologies

Cable One

Cabot

Cogent Communications Holdings

Celanese

CME Group

Cummins

CNA Financial

Canadian National Railway Company

CNO Financial Group

CRA International

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.

Dividend Champion, Contender, And Challenger Highlights: Week Of March 5

Blackstone Group

CVS Health

Enterprise Products Partners

Intercontinental Exchange

Intel

Kroger

Lowe's

PepsiCo

Cash is yielding over 4%, so a dividend growth investor can afford to be patient. February marked the first monthly decline in projected income since 2016 due to dividend cuts.

My Dividend Growth Portfolio February Update: Cash Is Not Trash

News for Amgen Stock (AMGN)